Breast Cancer Diagnostic Markers Licensed by Perlegen Sciences, Inc. in Agreement with University of Cambridge and Cancer Research Technology

MOUNTAIN VIEW, Calif. & LONDON--(BUSINESS WIRE)--Perlegen Sciences, Inc., The University of Cambridge, Cancer Research Technology Ltd (CRT) and its parent organization, Cancer Research UK, announced today that Perlegen has obtained an exclusive commercial license from Cambridge Enterprise Limited, the commercialisation office of Cambridge University, to the breast cancer markers identified through collaborative research between the parties that was previously announced in February, 2005.